Venker Eric

Venker Eric, who serves as President and CEO of Immunovant (IMVT), has been a consistent net seller across his Form 4 filings, with no open-market purchases recorded in the data. Over 72 transactions spanning two companies, his total sell value reached approximately $122.6 million, while his acquired value—largely from option exercises and equity grants—stood at zero. The pattern is unambiguous: every recent transaction involving a sale or disposition outweighs any mechanical or compensatory activity, and there is no instance of a "P" code indicating a conviction buy. The bulk of the selling has occurred in Roivant Sciences (ROIV), where Eric executed a series of large open-market sales throughout 2026. Notable transactions include a $6.99 million sale on July 27, a $6.05 million sale on May 22, and a $5.92 million sale on April 20, each paired with a $770,000 option exercise (code "M") on the same day. Smaller but still substantial ROIV sales appeared on June 24 (two tranches totaling roughly $6.6 million), March 17 ($5.65 million), February 13 ($5.30 million), and January 12 ($4.38 million). These sales were often accompanied by "F" codes—shares withheld for tax purposes—such as the $1.12 million and $191,435 withholdings in May and February, respectively, indicating that the option exercises were largely cashless conversions. In Immunovant, the activity is more mixed but still skewed toward disposition. On July 1, Eric exercised options worth $1.33 million and immediately sold shares back to the issuer (code "D") for $3.30 million, followed by a small open-market sale of $118,980 on July 2. A similar pattern occurred on April 1, with a $5.33 million exercise and an $8.41 million sale back to the issuer, plus two open-market sales on April 2 totaling roughly $343,000. Two zero-value grants (code "A") on April 7 represent compensation, not purchases. Across both tickers, the direction is clear: Eric has been monetizing equity consistently, with no recent buying activity whatsoever.